In a patient with chronic heart failure on furosemide 40 mg twice daily presenting with a hypertensive urgency, which antihypertensive should be added to protect the kidneys?

ACE Inhibitor or ARB for Renal Protection in CHF with Hypertensive Urgency

Add an ACE inhibitor (e.g., enalapril 2.5 mg daily) or ARB to the current furosemide regimen, as these agents provide superior renal protection, slow heart failure progression, and reduce mortality compared to all other antihypertensive classes in this population. 1

---

Rationale: ACE Inhibitors/ARBs Are Step 1 Therapy for CHF with Hypertension

The 2016 European Society of Cardiology guidelines designate ACE inhibitors as Step 1 therapy for hypertension in heart failure with reduced ejection fraction (HFrEF), with a Class I, Level A recommendation. 1 The 2022 ACC/AHA/HFSA heart failure guideline similarly recommends ACE inhibitors (or ARNi when feasible) as foundational therapy to reduce morbidity and mortality in patients with previous or current symptoms of chronic HFrEF. 2

ACE inhibitors remain the cornerstone of therapy for patients with chronic heart failure and moderate renal impairment (eGFR ≈30–60 mL/min). 1 They lower intraglomerular pressure, thereby conferring long-term renal protection even when serum creatinine rises modestly during initiation. 1

---

Why Not Other Antihypertensives?

Calcium Channel Blockers (e.g., Amlodipine)

Amlodipine is classified as Step 3 therapy by ESC guidelines—to be added only after ACE inhibitor, beta-blocker, mineralocorticoid receptor antagonist (MRA), and diuretic therapy have been optimized. 1 Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are absolutely contraindicated in systolic heart failure due to negative inotropic effects and worsened outcomes. 1

Thiazide Diuretics

Thiazides are more effective for hypertension than loop diuretics but should not be used as monotherapy when eGFR <30 mL/min (creatinine >2.0 mg/dL) because they are ineffective. 1 In this patient already on furosemide 40 mg BID, adding a thiazide would risk severe hypokalemia, hyponatremia, worsening renal function, and increased mortality without addressing the underlying heart failure pathophysiology. 1

Direct Vasodilators

Direct vasodilators have no specific role in chronic heart failure (Level A evidence). 1

---

Initiating an ACE Inhibitor in a Patient on Furosemide

Starting Dose and Titration

Start enalapril at 2.5 mg once daily (not the standard 5 mg dose) because the patient is currently on a diuretic. 3 The FDA label for enalapril explicitly states: "In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of enalapril maleate. If the diuretic cannot be discontinued, an initial dose of 2.5 mg should be used under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour." 3

Increase enalapril from 2.5 mg to 5 mg daily after 1–2 weeks if tolerated, then titrate to 10–20 mg daily (target 20–40 mg) to achieve doses proven to reduce cardiovascular mortality and HF hospitalizations. 1

Monitoring Protocol

After each dose increment, check blood pressure, renal function (creatinine/eGFR), and serum potassium at 1–2 weeks, then at 3 months and every 6 months thereafter. 1

A rise in serum creatinine up to 25–30% (or an absolute value <2.5 mg/dL) is acceptable and should not trigger discontinuation of the ACE inhibitor. 1 This modest, pharmacologically mediated eGFR reduction confers long-term renal protection by lowering intraglomerular pressure. 1

If the creatinine rise exceeds these thresholds, reduce the ACE inhibitor dose rather than discontinue it. 1

---

Managing Diuretic Therapy Concurrently

Furosemide Dose Optimization

The current furosemide dose (40 mg BID = 80 mg/day total) is appropriate for maintenance therapy in CHF. 2 The 2022 ACC/AHA/HFSA guideline states that the treatment goal of diuretic use is to eliminate clinical evidence of fluid retention using the lowest dose possible to maintain euvolemia. 2

If fluid overload persists after starting the ACE inhibitor, increase the furosemide dose before adding other agents. 1 When diuresis is inadequate in patients with creatinine ≈1.8 mg/dL, first increase the furosemide dose before adding other diuretics. 1

Loop diuretic monotherapy is preferred; uptitration of furosemide is safer and more effective than adding a thiazide when diuresis is inadequate. 1

Avoiding Thiazide Combination

Routine combination of loop diuretics and thiazides without first optimizing the loop dose is associated with hypokalemia, hyponatremia, worsening renal function, and increased mortality. 1

A thiazide should be added only synergistically with a high-dose loop diuretic in cases of severe, refractory fluid retention, with close monitoring of creatinine and electrolytes. 1

---

Potassium and Electrolyte Management

Discontinue Routine Potassium Supplementation

Concomitant administration of ACE inhibitors alone or in combination with potassium-retaining agents can prevent electrolyte depletion in most patients with heart failure taking a loop diuretic, making long-term oral potassium supplementation frequently unnecessary and potentially deleterious. 4

Patients on ACE inhibitors or ARBs alone or in combination with aldosterone antagonists frequently do not require routine potassium supplementation, and such supplementation may be deleterious, as these medications reduce renal potassium losses. 4

Concomitant administration of enalapril maleate with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics may lead to increases of serum potassium. 3

Monitoring Potassium

Check serum potassium and renal function 1–2 weeks after initiating or titrating any ACE inhibitor, then monthly for the first 3 months and every 3–6 months thereafter. 1

Target serum potassium range is 4.0–5.0 mmol/L. 1

---

Adding an Aldosterone Antagonist (MRA) for Additional Benefit

Once the ACE inhibitor is titrated to target dose, consider adding spironolactone 12.5–25 mg daily in patients with NYHA class III–IV symptoms, provided baseline potassium <5.0 mmol/L and creatinine <2.5 mg/dL. 1

Spironolactone provides both blood-pressure reduction and mortality benefit in heart failure. 1

Re-check serum potassium and creatinine 4–6 days after initiation, then every 5–7 days until values stabilize. 1

If potassium rises to 5.0–5.5 mmol/L, reduce the dose by 50%; discontinue if >5.5 mmol/L. 1

Co-administration of an SGLT2 inhibitor may mitigate hyperkalemia risk, allowing safer MRA use. 1

---

SGLT2 Inhibitor as Adjunctive Therapy

Start dapagliflozin 10 mg daily or empagliflozin 10 mg daily; these agents improve cardiovascular and renal outcomes and lower the risk of hyperkalemia in patients on RAAS blockade (hazard ratio ≈0.84). 1

SGLT2 inhibitors can be introduced concurrently with ACE inhibitor up-titration to facilitate rapid GDMT optimization. 1

---

Medications to Avoid

Stop all non-steroidal anti-inflammatory drugs (NSAIDs) immediately; they promote sodium retention, worsen renal function, and blunt diuretic efficacy. 1

Do not use thiazide diuretics as monotherapy when eGFR <30 mL/min (creatinine >2.0 mg/dL); they are ineffective unless combined with a loop diuretic. 1

Chronic use of positive inotropic agents increases mortality and should be avoided. 1

Calcium-channel blockers with negative inotropic effects (e.g., diltiazem, verapamil) are potentially harmful. 1

---

Critical Pitfalls to Avoid

Do not withhold ACE inhibitors or ARBs solely because of chronic kidney disease or modest blood pressure reductions; mortality benefit persists. 1

Do not discontinue ACE inhibitors or ARBs solely because of a modest eGFR decline; the long-term cardiovascular and renal benefits outweigh the transient creatinine rise. 1

Failing to monitor potassium levels regularly after initiating ACE inhibitor therapy can lead to serious complications. 4

Not discontinuing potassium supplements when initiating ACE inhibitors can lead to hyperkalemia. 4

---

Summary Algorithm

1. Start enalapril 2.5 mg daily (reduced dose due to concurrent diuretic use). 3
2. Monitor BP, creatinine, and potassium at 1–2 weeks. 1
3. Discontinue routine potassium supplementation (if any). 4
4. Titrate enalapril to 5 mg, then 10–20 mg daily over subsequent weeks. 1
5. Optimize furosemide dose (increase if fluid retention persists). 1
6. Add spironolactone 12.5–25 mg daily once ACE inhibitor is at target dose (if NYHA III–IV and K+ <5.0). 1
7. Consider SGLT2 inhibitor (dapagliflozin 10 mg or empagliflozin 10 mg daily). 1
8. Avoid NSAIDs, thiazide monotherapy, and calcium channel blockers (except amlodipine as Step 3 if needed). 1